Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen alleges patent infringement against Roche
The biotech company alleges that Roche’s Cera infringes six patents owned by the company covering erythropoietin (EPO) which forms the bases of its own anemia treatment, Epogen. Amgen
The biotech company alleges that Roche’s Cera infringes six patents owned by the company covering erythropoietin (EPO) which forms the bases of its own anemia treatment, Epogen. Amgen
Rectogesic is a topical nitroglycerin ointment indicated for the relief of pain associated with chronic anal fissures. In September 2004, the product was approved by the UK Medicines
Ranbaxy can appeal the decision, but it will not be able to market a product made using the patented intermediate compounds unless it prevails on appeal. In response
The original agreements, signed in 1997, were related to the development, manufacturing and co-promotion rights for all human cancer applications of Insegia, including stomach, esophageal, colorectal, and pancreatic
Additionally, in the alliance, Pfizer will apply VirtualScopics’ technology to ongoing clinical research in an effort to identify and validate image-based biomarkers correlating to clinical outcomes. The biomarkers
Under the terms of this agreement, Dendritic Nanotechnologies will build chemistries on proprietary Lumera surfaces, focusing efforts on using their expertise and patent holdings in the area of
The grant will be paid over two years and will support CollaGenex’s manufacturing and formulation development of incyclinide as well as preclinical studies that should advance the company’s
The phase I trial is designed to characterize the pharmacokinetic profile of two currently marketed drugs, identified by Stem Cell Therapeutics (SCT) as effective in non-clinical models of
The trial will recruit 50 patients with resected stage II or III melanoma who will be randomized to receive either Uvidem alone or Uvidem combined with peginterferon alpha-2b,
These data demonstrate the potential utility of INGN 241 in combination with Celebrex, a drug approved for the treatment of precancerous lesions of the colon, and exemplify the